Arcus Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. on June 12, 2018, covering events occurring on June 8, 2018. The filing addresses Item 5.02 regarding the appointment of certain officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
Effective June 8, 2018, Jennifer Jarrett was promoted from Chief Business Officer and Chief Financial Officer to Chief Operating Officer and Chief Financial Officer. Her responsibilities now include finance, investor relations, corporate communications, business and corporate development, strategic planning, and human resources.
Compensation and Outlook
- Salary Adjustment: Ms. Jarrett's annual base salary increased from $420,000 to $450,000, effective May 31, 2018.
- Equity Grant: She was granted a stock option to purchase 161,114 shares of common stock.
- Vesting Schedule: The options vest monthly over four years, contingent upon continued service.
The filing contains no specific guidance, outlook, or discussion of risks and contingencies beyond the standard executive appointment disclosure.
Investor Verification Points
- Confirm the effective date of the salary increase (May 31, 2018) versus the promotion date (June 8, 2018).
- Review the specific vesting terms and exercise price of the 161,114 stock options granted.
- Verify the impact of the expanded role on the company's strategic planning and business development functions.